GlassScriptPhysician profile
Houshang Farhadian
NPI 1427152727
$2,189.09
in general payments reported to CMS, 2019-2025
18 companies · $361 in 2025
The $361 reported for 2025 was less than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2020: $76.59 · 2021: $327 · 2022: $490 · 2023: $396 · 2024: $244 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $970 · Education: $31.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.85 |
| Education | $31.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $732.42 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Blueprint Medicines Corporation | $375.81 | 2022-2025 | Ayvakit |
| Genzyme Corporation | $187.81 | 2020-2025 | |
| Amgen INC. | $183.07 | 2022-2025 | Tezspire, Actimmune |
| Ars Pharmaceuticals Operations, INC. | $147.96 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $147.74 | 2020-2025 | Dupixent |
| Pfizer INC. | $93.82 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $52.59 | 2023-2025 | |
| Advanced Respiratory, INC | $42.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.80 | 2020-2021 | |
| Kaleo, INC. | $35.67 | 2022 | |
| Incyte Corporation | $23.78 | 2023 | Opzelura |
| Merck Sharp & Dohme LLC | $23.35 | 2023 | |
| Alk-Abello, INC | $22.82 | 2023 | Ragwitek, Odactra, Grastek |
| Horizon Therapeutics Plc | $20.57 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $19.95 | 2022 | |
| Bio Products Laboratory USA, INC. | $19.20 | 2019 | |
| Octapharma USA, INC. | $19.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Houshang Farhadian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.